Pilot trial of MEX-CD1 in dialysis for sepsis-associated AKI
The pilot trial of MEX-CD1 is currently evaluating its efficacy and safety as an adjunct to dialysis in adults with sepsis-associated acute kidney injury (AKI).
Company
Pharmaceutical intelligence for MEX-CD1 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.